CD40標靶治療的全球市場:臨床試驗，治療方法，市場機會的洞察(2025年)

Global CD40 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market Opportunity Insight 2025

出版日期: 2024年11月01日 | 出版商:

KuicK Research | 英文 110 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

CD40標靶治療已成為免疫治療研究的熱點，人們對利用CD40受體的潛力治療多種疾病越來越感興趣。儘管 CD40 標靶療法尚未批准用於臨床，但幾種有希望的候選療法目前正處於後期臨床開發階段。此外，預計更多候選藥物將在明年進入後期臨床試驗，從而擴大臨床開發中的 CD40 標靶療法庫。這些正在進行的研究和臨床試驗表明，CD40標靶治療可能成為未來幾年患病人群的重要治療選擇。

從歷史上看，CD40標靶治療的主要焦點是自體免疫疾病和發炎性疾病。然而，人們對探索 CD40 標靶療法治療癌症和其他疾病的潛力越來越感興趣。最近的研究擴大了 CD40 的治療範圍，包括 HIV 和 COVID-19 等傳染病，以及阿茲海默症和帕金森氏症等神經退化性疾病。此外，研究表明，CD40標靶治療可能對CD40訊號傳導路徑不直接參與疾病發作的疾病有效，例如涉及疾病進展和發炎的心血管疾病。

獨特技術和平台的出現極大地促進了 CD40 標靶療法的發展。一個著名的例子是 GenMab 的 DuoBody 平台，該平台能夠創建同時針對兩種不同抗原的雙特異性抗體。該技術已被用於開發幾種有前途的免疫療法，包括目前處於惡性實體瘤二期試驗的 CD40 標靶療法 GEN1042/BNT312。

總而言之，CD40 標靶療法尚未被批准用於臨床，但在多種疾病中是一個有前途且快速發展的研究和開發領域。隨著越來越多的治療方法進入臨床試驗以及競爭格局的加劇，CD40 標靶療法可能很快就會成為癌症、自體免疫疾病、傳染病等疾病治療的基石。

本報告提供全球CD40標靶治療市場相關調查，提供市場概要，以及藥物趨勢，臨床試驗趨勢，及加入此市場的主要企業競爭情形等資訊。

First CD40 Targeted Therapy Approval Expected By 2027
CD40 Targeted Therapies In Clinical Trials: > 20 Therapies
CD40 Inhibitors Clinical Trials Insight By Company, Country, Indication & Phase
CD40 Targeted Therapy Research & Development Trends By Indication
CD40 Targeted Therapy Market Trend Analysis By Region
CD40 Targeted Therapies Proprietary Technologies By Company

CD40 targeted therapies have become a focal point in immunotherapy research, with growing attention on harnessing the potential of the CD40 receptor to treat a variety of diseases. While no CD40 targeted therapies have yet been approved for clinical use, some promising candidates are currently undergoing late stage clinical development. Moreover, additional candidates are slated to enter late-stage trials within the next year, expanding the pool of CD40 targeted therapies in clinical development. These ongoing research and clinical trials suggest that CD40 targeted therapies could become a vital treatment option for patients with prevalent diseases in the coming years.

Historically, the primary focus of CD40 targeted therapies has been on autoimmune and inflammatory diseases. However, there is an increasing interest in exploring their potential for treating cancer and other conditions. More recent studies have expanded the scope of CD40 targeting to include infectious diseases, such as HIV and COVID-19, as well as neurodegenerative diseases like Alzheimer's and Parkinson's disease. Some research has also suggested that CD40 targeted therapies might be beneficial for diseases like cardiovascular conditions, where CD40's signaling pathway, although not directly involved in disease initiation, plays a role in disease progression and inflammation.

Over the years, various strategies have been employed to target the CD40 receptor and its ligand. These include traditional monoclonal antibodies as well as next-generation molecular therapeutics such as small interfering RNA (siRNA). While antibodies are developed either as CD40 agonists or as antagonists, CD40 targeted siRNAs aim to reduce CD40 protein expression by degrading CD40 mRNA. Several other conventional and next-generation approaches are undergoing active research and clinical trials to assess their safety and efficacy.

Nonetheless, antibody therapies remain the dominant approach in CD40 targeted research. Among the most advanced CD40/CD40L targeted antibodies are those for autoimmune and inflammatory diseases, with some entering phase 3 clinical trials. For example, Sanofi's Frexalimab, a promising anti CD40 antibody, is currently in phase 3 trials for autoimmune conditions. In the cancer domain, CD40 targeted antibodies are also making significant strides, with companies like Alligator Bioscience preparing to initiate phase 3 clinical trials for its lead candidate, mitazalimab, an anti-CD40 antibody for pancreatic ductal adenocarcinoma (PDA) and pancreatic cancer.

The development of CD40 targeted therapies has been greatly facilitated by the advent of proprietary technologies and platforms. One notable example is GenMab's DuoBody platform, which enables the creation of bispecific antibodies that can target two different antigens simultaneously. This technology has been leveraged to develop several promising immunotherapies, including its CD40 targeted therapy, GEN1042/BNT312, currently in phase 2 trial for malignant solid tumors.

As the field of CD40 targeted therapies evolves, the competitive landscape is becoming increasingly crowded, with many major pharmaceutical companies entering the arena. Notable players include Amgen, Sanofi, GenMab, BioNTech, and Biogen, all of which are investing heavily in this space. Collaborations between pharmaceutical companies and academic institutions have been essential in advancing the scientific understanding of CD40 targeted therapies, combining cutting edge research with clinical expertise to bring these therapies closer to market.

In conclusion, while CD40 targeted therapies have not yet been approved for clinical use, they represent a promising and rapidly developing area of research across a wide range of diseases. As more therapies enter clinical trials and the competitive landscape intensifies, it is clear that CD40 targeted therapies could become a cornerstone of treatment for cancer, autoimmune diseases, infectious diseases, and beyond in the near future.

1. Introduction To CD40 Targeted Therapies

1.1 Overview
1.2 Considering CD40 As Drug Target Over Other CD Markers
1.3 History & Evolution Of CD40 Targeting Therapies

2. CD40 Targeted Therapies - Mechanism Of Action

2.1 Agonist Mediated Activation Of CD40 Signaling
2.2 Antagonist-Mediated Inhibition Of CD40 Signaling

3. CD40 Targeted Therapeutic Approaches

3.1 Antibody Formats
3.2 Fusion Proteins
3.3 Peptides
3.4 Nucleic Acids

4. CD40 Targeted Therapy Research & Development Trends By Indication

4.1 Cancer
4.2 Neurological Diseases
4.3 Autoimmune & Inflammatory Disorders
4.4 Transplant Rejection
4.5 Microbial Infections

5. Global CD40 Targeted Therapy Market Outlook

5.1 Current Market Trends & Developments
5.2 Future Market Opportunities

6. CD40 Targeted Therapy Market Trend Analysis By Region

6.1 US
6.2 Europe
6.3 China
6.4 Japan
6.5 Australia

7. CD40 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase

7.1 Research
7.2 Preclinical
7.3 Phase I
7.4 Phase I/II
7.5 Phase II
7.6 Phase III

8. CD40 Targeted Therapies - Proprietary Technologies By Company

8.1 Alligator Bioscience - FIND Technology & Neo-X-Prime
8.2 Aprilbio - SAFA Platform
8.3 Biocytogen - RenMice
8.4 EnnoDC - Unnamed Platform
8.5 Genmab - DuoBody
8.6 Harbour BioMed - Harbour Mice & HBICE
8.7 Kyowa Kirin - REGULGENT
8.8 Strike Pharma - ADAC Technology Platform

9. Global CD40 Targeted Therapy Market Dynamics

9.1 Drivers & Opportunities
9.2 Challenges & Restraints

10. Competitive Landscape

10.1 Alligator Bioscience
10.2 Amgen
10.3 Biogen
10.4 BioNTech
10.5 Eledon Pharmaceuticals
10.6 EnnoDC
10.7 Genmab
10.8 Innovent Bio
10.9 Novartis
10.10 Sanofi
10.11 Tonix Pharmaceuticals
10.12 UCB

簡介目錄圖表

List of Figures

Figure 1-1: CD40 - Salient Features
Figure 1-2: CD40 Targeted Therapy Landscape - Major Milestones
Figure 2-1: CD40 Agonists - Mechanism of Action
Figure 3-1: Prominent Antibody Formats for Targeting CD40
Figure 4-1: OPTIMIZE-1 Phase 1b/2 (NCT04888312) Study - Initiation & Completion Year
Figure 4-2: Mitazalimab Phase 1 (NCT06205849) Study - Initiation & Completion Year
Figure 4-3: 2141-V11 Phase 1/2 (NCT05126472) Study - Initiation & Completion Year
Figure 4-4: 2141-V11 Phase 1 (NCT06455605) Study - Initiation & Completion Year
Figure 4-5: 2141-V11 Phase 1/2 (NCT05734560) Study - Initiation & Completion Year
Figure 4-6: ACT16877 Phase 2 (NCT04879628) Study - Initiation & Completion Year
Figure 4-7: FREVIVA Phase 3 (NCT06141486) Study - Initiation & Completion Year
Figure 4-8: FREXALT 3 (NCT06141473) Study - Initiation & Completion Year
Figure 4-9: HZNP-DAZ-301 Phase 3 (NCT06104124) Study - Initiation & Completion Year
Figure 4-10: HZNP-DAZ-303 Phase 3 (NCT06245408) Study - Initiation & Completion Year
Figure 4-11: VIBRANT Phase 2 (NCT05201469) Study - Initiation & Completion Year
Figure 4-12: CONTROL-RA Phase 2 (NCT05306353) Study - Initiation & Completion Year
Figure 4-13: PHOENYCS FLY Phase 3 (NCT06617325) Study - Initiation & Completion Year
Figure 4-14: SL0046 Phase 3 (NCT04976322) Study - Initiation & Completion Year
Figure 4-15: APB-A1 Phase 1b (NCT06557850) Study - Initiation & Completion Year
Figure 4-16: FABULINUS Phase 2 (NCT06111586) Study - Initiation & Completion Year
Figure 4-17: IRB23-1367 Phase 1/2 (NCT06111586) Study - Initiation & Completion Year
Figure 4-18: AT-1501-K102 Phase 1 (NCT05027906) Study - Initiation & Completion Year
Figure 4-19: BESTOW/AT-1501-K207 Phase 2 (NCT05983770) Study - Initiation & Completion Year
Figure 4-20: BESTOW-EXTENSION/AT-1501-K209 Phase 2 (NCT06126380) Study - Initiation & Completion Year
Figure 4-21: ANRS VRI06 Phase 1 (NCT04842682) Study - Initiation & Completion Year
Figure 4-22: HVTN 318 Phase 1 (NCT06665646) Study - Initiation & Completion Year
Figure 4-23: ANRS0407s - LKV.Cov40 Phase 1/2 (NCT06255626) Study - Initiation & Completion Year
Figure 8-1: Alligator Bioscience - FIND technology
Figure 8-2: Alligator Bioscience - Neo-X-Prime
Figure 8-3: Aprilbio - SAFA Antibody APB-A1
Figure 8-4: Genmab - DuoBody
Figure 8-5: Harbour BioMed - Harbour Mice
Figure 8-6: Harbour BioMed - HCAb
Figure 8-7: H2L2 & HCAb Platforms - Features
Figure 8-8: Harbour BioMed - HBICE
Figure 8-9: Kyowa Kirin - REGULGENT
Figure 8-10: ADAC Technology Platform - Features